ARTICLE | Company News
Aquila other research news
August 16, 1999 7:00 AM UTC
AQLA received a two-year $870,000 Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases to develop tuberculosis vaccines using AQLA's CD1 antigen presentation immune enhan...